S&T Bank Supernus Pharmaceuticals, Inc. Transaction History

S&T Bank

$381 Million
Q3 2024

A detailed history of S&T Bank transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, S&T Bank holds 123,333 shares of SUPN stock, worth $4.39 Million. This represents 1.01% of its overall portfolio holdings.

Number of Shares

123,333

Previous 127,636 3.37%

Holding current value

$4.39 Million

Previous $3.41 Million 12.65%

% of portfolio

1.01%

Previous 0.87%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$25.77 - $35.16 $110,888 - $151,293	-4,303 Reduced 3.37%	123,333 $3.85 Million
Q2 2024 Aug 14, 2024	SELL	$25.99 - $33.85 $1.25 Million - $1.62 Million	-47,928 Reduced 27.3%	127,636 $3.41 Million
Q1 2024 May 15, 2024	SELL	$27.11 - $35.17 $373,901 - $485,064	-13,792 Reduced 7.28%	175,564 $5.99 Million
Q4 2023 Feb 14, 2024	SELL	$22.72 - $29.68 $595,763 - $778,268	-26,222 Reduced 12.16%	189,356 $5.48 Million
Q3 2023 Nov 14, 2023	SELL	$27.57 - $32.91 $156,184 - $186,435	-5,665 Reduced 2.56%	215,578 $5.94 Million
Q2 2023 Aug 14, 2023	SELL	$29.91 - $38.73 $75,732 - $98,064	-2,532 Reduced 1.13%	221,243 $6.65 Million
Q1 2023 May 09, 2023	SELL	$34.93 - $42.03 $2.29 Million - $2.75 Million	-65,494 Reduced 22.64%	223,775 $8.11 Million
Q4 2022 Feb 13, 2023	SELL	$31.09 - $37.88 $371,743 - $452,931	-11,957 Reduced 3.97%	289,269 $10.3 Million
Q3 2022 Nov 10, 2022	SELL	$28.79 - $35.41 $350,201 - $430,727	-12,164 Reduced 3.88%	301,226 $10.2 Million
Q2 2022 Aug 10, 2022	SELL	$25.33 - $34.25 $74,368 - $100,558	-2,936 Reduced 0.93%	313,390 $9.06 Million
Q1 2022 May 16, 2022	SELL	$28.51 - $32.9 $6,927 - $7,994	-243 Reduced 0.08%	316,326 $10.2 Million
Q4 2021 Feb 14, 2022	BUY	$26.37 - $34.22 $12,420 - $16,117	471 Added 0.15%	316,569 $9.23 Million
Q3 2021 Nov 12, 2021	SELL	$23.54 - $31.39 $60,827 - $81,111	-2,584 Reduced 0.81%	316,098 $8.43 Million
Q2 2021 Aug 13, 2021	SELL	$26.72 - $33.19 $22,738 - $28,244	-851 Reduced 0.27%	318,682 $9.81 Million
Q1 2021 May 17, 2021	SELL	$24.15 - $31.45 $14,755 - $19,215	-611 Reduced 0.19%	319,533 $8.37 Million
Q4 2020 Feb 17, 2021	BUY	$17.7 - $25.81 $7,186 - $10,478	406 Added 0.13%	320,144 $8.06 Million
Q3 2020 Nov 16, 2020	BUY	$20.2 - $25.05 $380,810 - $472,242	18,852 Added 6.27%	319,738 $6.66 Million
Q2 2020 Aug 14, 2020	SELL	$17.09 - $24.89 $79,092 - $115,190	-4,628 Reduced 1.51%	300,886 $7.15 Million
Q1 2020 May 14, 2020	BUY	$14.45 - $24.69 $746,472 - $1.28 Million	51,659 Added 20.35%	305,514 $5.5 Million
Q4 2019 Feb 13, 2020	BUY	$19.93 - $29.13 $30,532 - $44,627	1,532 Added 0.61%	253,855 $6.02 Million
Q3 2019 Nov 14, 2019	BUY	$25.47 - $33.37 $248,689 - $325,824	9,764 Added 4.03%	252,323 $6.94 Million
Q2 2019 Aug 13, 2019	BUY	$29.96 - $38.87 $2.38 Million - $3.09 Million	79,525 Added 48.78%	242,559 $8.03 Million
Q1 2019 May 14, 2019	BUY	$32.77 - $41.99 $5.34 Million - $6.85 Million	163,034 New	163,034 $5.71 Million

Others Institutions Holding SUPN

# of Institutions

281

Shares Held

60.6M

Call Options Held

27.7K

Put Options Held

11.3K

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.9B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of S&T Bank, based on Form 13F filings with the SEC.

News

Stay updated on S&T Bank with notifications on news.

Account